A two-center nonrandomized retrospective study to assess the efficacy of hyperimmune globulin in the treatment of patients with COVID-19
Epidemiology and Infectious Diseases · 22.02.2026 · 31 (1) · 15-28
DOI: 10.17816/eid696246 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epidemiology and Infectious Diseases, online erschienen am 22.02.2026. Verfasst von Tamara A. Igityan und 4 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Despite the availability of vaccines and antiviral drugs, there is still a need for effective therapeutic strategies for patients with COVID-19, especially those at high risk of severe disease. Hyperimmune globulin against COVID-19 is a promising immunologic agent. However, real-world data on its efficacy, particularly that on treatment timing, are limited and require further investigation. AIM: This study aimed to evaluate the efficacy and safety of hyperimmune globulin (COVID-globulin) in the treatment of hospitalized patients with COVID-19 and to determine the optimal timing of its use. METHODS: This was a retrospective, cohort study, conducted at 2 clinical sites in Moscow from January 1, 2022 to January 31, 2023. The study included 148 patients aged 20 to 94 years with confirmed SARS-CoV-2 infection. The main group (n = 88) comprised patients who received COVID-globulin in addition to standard therapy, whereas the comparison group (n = 60) comprised patients who received standard therapy alone. The primary efficacy endpoint was mortality in the compared groups by discharge (days 7–10 of hospitalization). The secondary endpoint included assessment of clinical parameters, laboratory and radiographic findings over time. RESULTS: The overall mortality rate in the main group (8.0%) did not differ significantly from that in the control group (6.7%) at discharge (p = 1.000). However, a correlation was identified between the efficacy of COVID-globulin and the timing of its inclusion in the treatment regimen. Administration of the drug within the first 7 days of disease onset demonstrated relevant clinical advantages compared with later administration. It resulted in a significant reduction in the median length of hospitalization from 15 (IQR, 13.5–19) to 10 (IQR, 8–14) days (p 0.001), improvement in SpO2 values (97% [96–98] vs. 95% [94–96]; p = 0.024), and a more pronounced decrease in C-reactive protein levels by discharge (8.1 mg/L [2–19] vs. 23 mg/L [19–43]; p = 0.023). In the main group, complete resolution of pulmonary infiltrative changes on computed tomography by the time of discharge was also observed significantly more frequently (56.5% vs. 10.5% in the control group; p 0.001). No adverse events associated with drug administration were recorded. CONCLUSION: The use of COVID-globulin in hospitalized patients with COVID-19 did not result in a significant reduction in mortality. However, we demonstrated significant efficacy of this therapeutic strategy when COVID-globulin was used during the first week of illness, as evidenced by a shorter duration of hospitalization, more rapid resolution of respiratory dysfunction, and resolution of inflammation.
Zitieren
APA
Igityan, T. A., Burgasova, O. А., Tetova, V. B., Ogarkova, D. A., & Tokmalaev, A. K. (2026). A two-center nonrandomized retrospective study to assess the efficacy of hyperimmune globulin in the treatment of patients with COVID-19. Epidemiology and Infectious Diseases, 31(1), 15-28. https://doi.org/10.17816/eid696246
Vancouver
Igityan TA, Burgasova OА, Tetova VB, Ogarkova DA, Tokmalaev AK. A two-center nonrandomized retrospective study to assess the efficacy of hyperimmune globulin in the treatment of patients with COVID-19. Epidemiology and Infectious Diseases. 2026;31(1):15-28. doi:10.17816/eid696246
BibTeX
@article{Igityan2026,
author = {Igityan, Tamara A. and Burgasova, Olga А. and Tetova, Vera B. and Ogarkova, Daria A. and Tokmalaev, Anatoly K.},
title = {A two-center nonrandomized retrospective study to assess the efficacy of hyperimmune globulin in the treatment of patients with COVID-19},
journal = {Epidemiology and Infectious Diseases},
year = {2026},
volume = {31},
number = {1},
pages = {15--28},
doi = {10.17816/eid696246}
}
EUVIMED